EXAS News and Press, Exact Sciences Corporation From 05/01/24

2024-05-01 02:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-24 09:10:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. Our portfolio outperformed the Russell Midcap® Growth Index in Q1 due to balance...

2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...

2024-04-19 03:54:17 ET Summary ARK Invest's 13F portfolio value decreased by 15% this quarter, with the number of holdings increasing from 223 to 230. The top three holdings in the portfolio are Coinbase Global, Tesla, and Block, making up around 20% of the assets. ARK Invest ...

2024-04-15 11:30:02 ET William Blair analyst issues OUTPERFORM recommendation for EXAS on April 15, 2024 10:21AM ET. The previous analyst recommendation was Outperform. EXAS was trading at $68.965 at issue of the analyst recommendation. The overall analyst consensus : BU...

2024-04-15 06:19:49 ET More on Exact Sciences Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau Exact Sciences Corporation (EXAS) Q4 2023 Earnings Call Transcript Exact Sciences Corporation 2023 Q4 - Results - Earnings Call Presentation Exact ...

Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. ...

2024-04-11 15:05:51 ET More on Exact Sciences Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau Exact Sciences gains after data for novel cancer screening test Exact Sciences GAAP EPS of -$0.27 beats by $0.21, revenue of $647M beats by $7.3M ...

First analysis from ASCEND-2 confirms high detection rates and specificity achieved with multi-biomarker approach in most aggressive cancers and those with no standard-of-care screening test 1 Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic t...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024. Following the release, company management will...